NeuroBytes: Discontinuation of Multiple Sclerosis Disease Modifying Therapies in Later Life
Course Description
With the expanding number of DMTs in MS, patients are living longer and the prevalence of MS in older adults is increasing. DMTs are very good at preventing relapse associated worsening, but most cannot stop progression of disease that happens independent of relapse activity, which tends to be the leading cause of disability accrual in older adults. Randomized trials of DMTs excluded patients older than 55. DISCOMS is a recently published phase 4, randomized, multi-center, single-blind, non-inferiority trial which evaluated patients 55 years or older with any type of MS to see if those who discontinued DMT were at higher risk of disease recurrence. We aim to review the ways that MS patients accrue disability and recently published data regarding discontinuing DMT in older adults to better inform decisions of patients and providers who are considering DMT cessation.
Learning Objectives
As a result of this program the learner will be able to:
- Better inform their Multiple Sclerosis patients of the risks and benefits of discontinuing disease modifying therapies later in life.
Date of Release
June 4, 2024
Confidentiality of Data
All material © American Academy of Neurology Institute unless otherwise indicated. All rights reserved. See complete
Terms of Use.
Faculty & Disclosures
DONALD LANFAN, MD, PharmD
PGY-4 Neurology Resident
New York Presbyterian - Wiell Cornell
New York, NY
*Dr. Langan has nothing to disclose.
Editor
Reviewer
PGY-4 Neurology Resident
New York Presbyterian - Wiell Cornell
New York, NY
*Dr. Langan has nothing to disclose.
Editor
REBECCA G. STRAUS FRABER, MD
Associate Professor of Neurology
Columbia University Medical School
New York, NY
Dr. Straus Farber has received personal compensation in the range of $0-$499 for serving as a Consultant for Genentech. Dr. Straus Farber has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for FKB Law. The institution of Dr. Straus Farber has received research support from Biogen. The institution of Dr. Straus Farber has received research support from Novartis.
Reviewer
ADAM QUICK, MD
Associate Professor of Neurology
The Ohio State university Wexner Medical Center
Columbus, OH
*Dr. Quick has nothing to disclose.
Voiceover Artist
BENJAMIN STODDART
Senior Trainee Education Administrator
American Academy of Neurology
Minneapolis, MN
Mr. Stoddart has nothing to disclose
NeuroBytes Staff
Xiaoyu Sun, Associate Director, eLearning
Minneapolis, MN
*Ms. Sun has nothing to disclose.
Robert Rook, Manager, eLearning
Minneapolis, MN
*Mr. Rook has nothing to disclose.